+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
New

Crohn’s Disease Epidemiology Analysis and Forecast to 2032

  • PDF Icon

    Report

  • 47 Pages
  • July 2023
  • Region: Global
  • GlobalData
  • ID: 5147743

Crohn’s Disease Epidemiology Report Overview

The number of the diagnosed prevalent cases of Crohn’s Disease (CD) in the 8MM was 1,626,752 in 2022. The number of diagnosed prevalent cases is further projected to grow by more than 4% during the forecast period at an AGR of 0.42% till 2032. Crohn’s disease (CD) is a type of inflammatory bowel disease (IBD) characterized by chronic inflammation of the gastrointestinal tract, which can lead to abdominal pain, severe diarrhea, fatigue, weight loss, and malnutrition. It most commonly affects the end of the small intestine (the ileum) where it joins the beginning of the colon. Inflammation caused by CD can involve different areas of the digestive tract in different people, most commonly the small intestine. This inflammation often spreads into the deeper layers of the bowel.

This report provides an overview of the risk factors, comorbidities, and the global and historical epidemiological trends for CD in the eight major markets (8MM: US, France, Germany, Italy, Spain, UK, Japan, and Canada). The report includes a 10-year epidemiology forecast for the diagnosed incident cases and diagnosed prevalent cases of CD. The diagnosed incident cases and diagnosed prevalent cases of CD are segmented by age (for all ages in 10-year age groups for ages 0-9 years up to 80 years and older), and sex. The report also provides the diagnosed prevalent cases of fistulizing CD as well as diagnosed prevalent cases of CD in remission in each of the severity segments.

Crohn’s Disease Epidemiology Segmentation by Countries

The epidemiological trends for CD are covered for the eight major markets including the US, France, Germany, Italy, Spain, UK, Japan, and Canada. In 2022, the US accounted for the largest number of both diagnosed incident cases and diagnosed prevalent cases of CD. However, as per the forecasts, while France is expected to account for the lowest number of diagnosed incident cases of CD, Japan will have the lowest number of diagnosed prevalent cases of CD in 2032. Any changes in the number of cases are mainly attributed to the changing population demographics in the 8MM and changing diagnosed prevalence rates based on trend analysis in the US, France, Spain, the UK, and Japan.

Crohn’s Disease Epidemiology Segmentation by Age-Specific Diagnosed Prevalent Cases

The key age-groups considered in the CD epidemiology report are 0-9, 10-17, 18-29, 30-39, 40-49, 50-59, 60-69, 70-79, and >80 years. In 2022, for the 8MM combined, adults ages 30-39 years contributed the highest proportion of the diagnosed prevalent cases of CD, followed by 18-29 years and 50-59 years respectively.

Crohn’s Disease Epidemiology Segmentation by Sex-Specific Diagnosed Prevalent Cases

The key sex-specific groups in the CD epidemiology analysis are males and females. In 2022, the number of diagnosed prevalent cases of CD was higher in females than in males in the 8MM combined. Among the 8MM, Japan had the largest difference in the diagnosed prevalent cases of CD between women and men, while, Spain had the smallest variation in the number of diagnosed prevalent cases between men and women.

Crohn’s Disease Epidemiology Segmentation by Severity Levels of Diagnosed Prevalent Cases

The main severity levels in the diagnosed prevalent cases of CD were mild, moderate, and severe. In 2022, out of the diagnosed prevalent cases of CD in the 8MM, mild cases contributed the highest proportion among the pediatric age group and among the adult age group. This trend was consistent across the 8MM, except in the US and Italy where moderate cases contributed the highest proportion in the pediatric as well as adult CD patients.

Segments Covered in this Report.

Crohn’s Disease Epidemiology Country-wise Outlook (2022-2032, Number of Cases)

  • The US
  • France
  • Germany
  • Italy
  • Spain
  • UK
  • Japan
  • Canada

Crohn’s Disease Epidemiology Age-Specific Outlook (2022-2032, Number of Cases)

  • 0-9
  • 10-17
  • 18-29
  • 30-39
  • 40-49
  • 50-59
  • 60-69
  • 70-79
  • >80

Crohn’s Disease Epidemiology Sex-Specific Outlook (2022-2032, Number of Cases)

  • Female
  • Males

Crohn’s Disease Epidemiology Severity Level Outlook (2022-2032, Number of Cases)

  • Mild
  • Moderate
  • Severe

Scope

This report provides an overview of the risk factors, comorbidities, and the global and historical epidemiological trends for CD in the eight major markets (8MM: US, France, Germany, Italy, Spain, UK, Japan, and Canada). The report includes a 10-year epidemiology forecast for the diagnosed incident cases and diagnosed prevalent cases of CD. The diagnosed incident cases and diagnosed prevalent cases of CD are segmented by age (for all ages in 10-year age groups for ages 0-9 years up to 80 years and older), and sex. The report also provides the diagnosed prevalent cases of fistulizing CD as well as diagnosed prevalent cases of CD in remission in each of the severity segments. This epidemiology forecast for CD is supported by historical data obtained from peer-reviewed articles and population-based studies. The forecast methodology was kept consistent across the 8MM to allow for a meaningful comparison of the forecast incident and prevalent cases of CD across these markets.

Reasons to Buy

The CD epidemiology series will allow you to:

  • Develop business strategies by understanding the trends shaping and driving the global CD market.
  • Quantify patient populations in the global CD market to improve product design, pricing, and launchplans.
  • Organize sales and marketing efforts by identifying the age groups that present the best opportunities for CD therapeutics in each of the markets covered.

Table of Contents

Table of Contents

1 Crohn’s Disease: Executive Summary
1.1 Catalyst

1.2 Related reports

1.3 Upcoming reports

2 Epidemiology
2.1 Disease background

2.2 Risk factors and comorbidities

2.3 Global and historical trends

2.4 8MM forecast methodology

2.4.1 Sources

2.4.2 Forecast assumptions and methods

2.4.3 Forecast assumptions and methods: diagnosed incident cases of CD

2.4.4 Forecast assumptions and methods: diagnosed prevalent cases of CD

2.4.5 Forecast assumptions and methods: diagnosed prevalent cases of CD by severity, diagnosed prevalent cases of fistulizing CD by severity, and diagnosed prevalent cases of CD in remission by severity

2.5 Epidemiological forecast for Crohn’s disease (2022-32)

2.5.1 Diagnosed incident cases of CD

2.5.2 Age-specific diagnosed incident cases of CD

2.5.3 Sex-specific diagnosed incident cases of CD

2.5.4 Diagnosed prevalent cases of CD

2.5.5 Age-specific diagnosed prevalent cases of CD

2.5.6 Sex-specific diagnosed prevalent cases of CD

2.5.7 Diagnosed prevalent cases of CD by severity

2.5.8 Diagnosed prevalent cases of fistulizing CD by severity

2.5.9 Diagnosed prevalent cases of CD in remission by severity

2.6 Discussion

2.6.1 Epidemiological forecast insight

2.6.2 COVID-19 impact

2.6.3 Limitations of the analysis

2.6.4 Strengths of the analysis

3 Appendix
3.1 Bibliography

3.2 Primary Research - Prescriber Survey

3.3 About the Authors

3.3.1 Epidemiologist

3.3.2 Reviewers

3.3.3 Vice President of Disease Analysis and Intelligence

3.3.4 Global Head and EVP of Healthcare Operations and Strategy

Contact the Publisher